Moderna

MRNA

94.160
USD
-25.02
(-20.99%)
Market Closed
Volume
191,461
EPS
0
Div Yield
0
P/E
-4
Market Cap
20,684,350,374

Signals

Abdilatif
8 months ago
sell
MRNA@101.02
2024-02-01 09:45
Profit
357
Abdilatif
8 months ago
sell
MRNA@101.83
2024-01-29 10:09
Profit
-175

Related Instruments

AZN
2.040
(2.58%)
81.200 USD
B
BNTX
-5.530
(-6.42%)
80.570 USD
GSK
0.865
(2.23%)
39.650 USD
JNJ
2.930
(1.86%)
160.770 USD
M
MODN
0.030
(0.10%)
30.000 USD
N
NVAX
-0.250
(-1.95%)
12.560 USD
PFE
0.115
(0.38%)
30.650 USD

News

Title: Moderna

Sector: Healthcare
Industry: Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.